915087-33-1

Enzalutamide (MDV3100) is an androgen receptor (AR) antagonist (IC50=36 nM in LNCaP) that activates autophagy, exhibits antitumor activity, and is commonly used in treating desmoplasia-resistant prostate cancer.

Enzalutamide-D6 is a deuterium-labeled variant of Enzalutamide (T6002) (MDV3100), an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells.

Enzalutamide carboxylic acid is an antagonist of androgen receptor (AR) .

Enzalutamide-D3 is a deuterium-labeled form of the androgen receptor antagonist Enzalutamide (T6002), retaining potent anti-androgen and antineoplastic activity with an IC50 of 36 nM in LNCaP prostate cancer cells, and is primarily used in pharmacokinetic, metabolic tracing, and drug interaction studies.

Enzalutamide-D6 (Standard) is a reference standard of Enzalutamide-D6 intended for quantitative analysis, quality control, and related biochemical research applications. Enzalutamide-d6 (MDV3100-d6) is a deuterium-labeled variant of Enzalutamide (MDV3100), an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells.